A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
← catalyst calendarNCT06879041 · readout in 971 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
136estimated
Sites
16
Countries
Australia, South Africa, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-10 | actual | When the study began enrolling |
| Primary completion | 2029-04-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-04-16 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration-Resistant Prostate Cancer
Interventions
- Drug: AZD2287
- Drug: AZD2275
- Drug: AZD2284
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse event (AEs)
measured Part A: Up to Day 28; Part B: Up to 5 years
Number of participants with Dose Limiting Toxicities (DLTs)
measured Part B: Up to 84 days of receiving AZD2284
Estimates of residence time
measured Part A: Up to 8 days after a dose of AZD2287
Absorbed radiation doses for AZD2287 and AZD2284
measured Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
Compare organ uptake of AZD2287 with and without pre-dose administration of AZD2275
measured Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
Tumor uptake of AZD2287 in selected regions of interest on SPECT/CT and/or planar images
measured Part A: Up to 8 days after a dose of AZD2287; Part B: Up to 7 days after a dose of AZD2287
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed